肿瘤生物学对非小细胞肺癌脑转移患者生存及放疗反应的影响
单中心回顾性研究纳入1989至2014年1920例非小细胞肺癌脑转移患者共6312个病灶,比较ALK重排、EGFR突变、野生型腺癌和鳞癌脑转移的自然史及放疗反应。ALK+和EGFR+患者生存优于野生型腺癌和鳞癌,但ALK+患者颅内局部失败、远处失败和放射性坏死风险更高,EGFR+患者最低。
要点
- ALK+脑转移患者中位生存49.2个月,EGFR+为20.3个月,野生型腺癌为10.0个月。
- 鳞癌脑转移中位生存5.4个月,低于腺癌的8.8个月。
- ALK+患者放射性坏死风险显著高于其他亚型(HR 5.77)。
核心结论
- ALK+和EGFR+状态与非小细胞肺癌脑转移患者生存改善相关。
- ALK+脑转移患者颅内控制较差,EGFR+患者颅内控制最好。
研究设计与样本
- 单中心三级医疗机构的回顾性研究,纳入1989年至2014年诊断的非小细胞肺癌脑转移患者1920例,共6312个脑转移灶。
- 主要结局为总生存,次要结局包括局部失败、颅内远处失败和放射性坏死。
- 总生存采用Cox比例风险回归建模,次要结局采用多因素竞争风险回归建模。
主要发现
- 鳞癌组织学中位生存5.4个月,腺癌为8.8个月(P < .01)。
- ALK+患者中位生存49.2个月,EGFR+为20.3个月,野生型腺癌为10.0个月(P < .01)。
- 接受estimated glomerular filtration rate抑制剂治疗(HR 0.66;P < .01)和血管内皮生长因子抗体治疗(HR 0.65;P < .01)可独立于突变状态提高生存。
- 在2056个接受立体定向放射外科治疗的病灶中,鳞癌12个月局部失败累积发生率15%,腺癌为10%(HR 1.26;P = .04)。
- ALK+患者局部失败率10%(HR 2.00;P = .05)、远处失败率39%(HR 2.94;P < .01)、放射性坏死率18%(HR 5.77;P < .01);EGFR+患者局部失败率5%(HR 0.46;P = .04)、远处失败率3%(HR 0.13;P = .04)。
临床怎么用
- 对非小细胞肺癌脑转移患者,应结合ALK、EGFR等分子分型评估生存预后和颅内控制策略。
- ALK+脑转移患者接受立体定向放射外科治疗后需密切监测局部失败、远处颅内失败和放射性坏死。
- EGFR+脑转移患者接受立体定向放射外科治疗后颅内控制较好。
局限性
- 研究为单中心回顾性设计,结果可能受选择偏倚影响。
- 研究跨越1989至2014年,治疗方式和分子检测手段随时间变化可能影响结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the natural history and response to radiation therapy among ALK-rearranged, EGFR-mutated, wild-type adenocarcinoma, and squamous cell non-small cell lung cancer (NSCLC) brain metastases. METHODS AND MATERIALS: Patients with NSCLC brain metastasis diagnosed from 1989 through 2014 at a single tertiary-care institution were included. The primary outcome was overall survival, whereas secondary outcomes included local failure, distant intracranial failure, and radiation necrosis. Cox proportional hazards regression was used to model overall survival; multivariate competing risks regression was used to model secondary outcomes. RESULTS: Within the study period, 1920 patients presented with 6312 brain metastases. Squamous histology was associated with poorer median survival compared with adenocarcinomas (5.4 vs 8.8 months, P < .01). Median survival was greatest among ALK+ patients (49.2 months), followed by EGFR+ (20.3 months), and wild-type adenocarcinomas (10.0 months, P < .01). Treatment with estimated glomerular filtration rate inhibitors (hazard ratio [HR], 0.66; P < .01) and vascular endothelial growth factor antibodies (HR, 0.65; P < .01) increased survival independent of mutational status. Among 2056 lesions treated with stereotactic radiosurgery, the 12-month cumulative incidence of local failure was significantly greater among squamous cell carcinomas relative to adenocarcinomas (15% vs 10%, HR, 1.26; P = .04). Patients with ALK+ metastases experienced higher rates of local failure (10%; HR, 2.00; P = .05), distant failure (39%; HR, 2.94; P < .01), and radiation necrosis (18%; HR, 5.77; P < .01), whereas EGFR+ patients experienced the lowest rates of local failure (5%; HR, 0.46; P = .04) and distant failure (3%; HR, 0.13; P = .04). CONCLUSIONS: Advances in precision medicine have increased survival among select patients with NSCLC. In the present investigation, ALK+ and EGFR+ status were associated with improved survival. However, patients with ALK+ metastases have poor intracranial control relative to EGFR+ metastases, possibly because of limited intracranial penetration of crizotinib compared with estimated glomerular filtration rate inhibitors. Future investigations are warranted to determine the optimal management of ALK+ brain metastases with the introduction of second-generation ALK inhibitors.
引用
- Miller JA, Kotecha R, Ahluwalia MS, et al. The impact of tumor biology on survival and response to radiation therapy among patients with non-small cell lung cancer brain metastases. Pract Radiat Oncol. 2017. PMID: 28254368. doi:10.1016/j.prro.2017.01.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。